Results for “dementia”
Alzheimer Disease
** Alzheimer disease is the world’s most common cause of dementia, a progressive brain disorder that robs individuals of memory, identity, and independence, affecting millions and driving urgent research and public‑health action. **CONTENT:** ## Overview Alzheimer disease (AD) is a chronic, progressive neurodegenerative disorder that accounts for **60‑80 % of all dementia cases** worldwide. First identified in the early 20th century, it is characterized pathologically by extracellular **amyloid‑β plaques** and intracellular **neurofibrillary tangles** composed of hyper‑phosphorylated tau protein. Clinically, patients experience a relentless decline in memory, language, visuospatial skills, and executive function, eventually losing the ability to perform basic activities of daily living. Globally, an estimated **55 million people** live with dementia, and AD is the leading contributor. In the United States alone, **≈ 6.2 million Americans aged ≥ 65** were living with AD in 2023, making it the **6th leading cause of death**. The disease imposes a staggering economic burden—U.S. health‑care costs exceeded **$300 billion** in 2022, with informal caregiving adding billions more. Despite these numbers, definitive disease‑modifying therapies remain elusive, underscoring the importance of early detection, risk‑reduction strategies, and supportive care. ## Background & Origins The story of Alzheimer disease begins with **Alois Alzheimer** (1864‑1915), a German psychiatrist and neuropathologist. In **1901**, Alzheimer began treating **Auguste Deter**, a 51‑year‑old woman who presented with progressive memory loss, language disturbances, and personality changes. After Deter’s death in **1906**, Alzheimer performed a post‑mortem examination, discovering **neuronal loss, cortical atrophy, and the hallmark plaques and tangles**. He presented these findings at the **Tübingen meeting of the German Psychiatric Society in 1906**, and later published the seminal paper **“Über eine eigenartige Erkrankung der Hirnrinde”** in **1910**, coining the term “Alzheimer’s disease” for this distinct clinical‑pathological entity. For decades the condition was considered a rare, “senile” form of dementia, but epidemiologic studies in the 1970s and 1980s revealed its true prevalence. The **NINCDS‑ADRDA criteria (1984)** and later the **DSM‑5 (2013)** standardized diagnosis, while advances in neuroimaging and cerebrospinal fluid biomarkers transformed AD from a purely clinical diagnosis to one supported by objective laboratory evidence. ## Major Achievements & Milestones **First cholinesterase inhibitor approval (1996):** The FDA approved **donepezil** (Aricept), the first drug shown to modestly improve cognition and daily functioning in mild‑to‑moderate AD, inaugurating a new therapeutic class. **Discovery of amyloid‑β peptide (1984):** **George Glenner** and **C. M. Glenner** isolated the 4‑kDa amyloid‑β fragment, confirming that amyloid plaques are composed of a specific peptide derived from the amyloid precursor protein (APP). This finding redirected research toward the “amyloid cascade hypothesis.” **Genetic breakthroughs (1991‑1995):** Mutations in **APP (1991)**, **PSEN1 (1995)**, and **PSEN2 (1995)** were linked to early‑onset familial AD, while the **APOE ε4 allele** was identified as the strongest genetic risk factor for late‑onset AD in **1995**, providing a genetic framework for risk stratification. **First disease‑modifying antibody (2021):** The FDA granted accelerated approval to **aducanumab (Aduhelm)**, an anti‑amyloid monoclonal antibody, marking the first therapy aimed at reducing amyloid plaques, albeit amid controversy over clinical efficacy. **Leqembi approval (2023):** **Lecanemab**, another anti‑amyloid antibody, received full FDA approval after the **CLARITY‑AD trial** demonstrated a statistically significant slowing of cognitive decline, offering renewed hope for disease‑modifying treatment. ## Timeline - **1906**: Alois Alzheimer presents the first case (Auguste Deter) at the Tübingen meeting. - **1910**: Publication of Alzheimer’s landmark paper describing plaques and tangles. - **1976**: First epidemiologic study (the “Nun Study”) highlights AD prevalence in aging populations. - **1984**: NINCDS‑ADRDA criteria standardize clinical diagnosis; amyloid‑β peptide identified. - **1996**: FDA approval of donepezil, the first cholinesterase inhibitor for AD. - **2003**: FDA approves memantine, an NMDA‑receptor antagonist for moderate‑to‑severe AD. - **2021**: FDA grants accelerated approval to aducanumab, the first amyloid‑targeting antibody. - **2023**: Lecanemab receives full FDA approval after robust phase‑III trial results. ## Impact & Legacy Alzheimer disease reshaped modern neurology, geriatrics, and public‑health policy. Its prevalence has driven **global initiatives** such as the **World Health Organization’s Global Action Plan on the Public Health Response to Dementia (2017‑2025)** and the **U.S. National Alzheimer’s Project Act (2009)**, which funds research, caregiver support, and public awareness campaigns. Culturally, AD has entered the collective consciousness through literature, film, and advocacy—think of the Pulitzer‑winning memoir **“The Longest Day”** or the Oscar‑winning documentary **“Alive Inside.”** The disease also spurred ethical debates about **diagnostic disclosure**, **advance directives**, and **clinical trial design**, influencing legislation on research funding and patient rights. ## Records & Notable Facts - **Prevalence:** AD accounts for **≈ 70 % of all dementia cases** worldwide. - **Mortality:** It is the **6th leading cause of death** in the United States (2022 CDC data). - **Economic impact:** U.S. health‑care expenditures for AD surpassed **$300 billion** in 2022. - **Gender disparity:** About **two‑thirds** of AD patients are women, reflecting longer life expectancy and possible biological factors. - **First diagnostic biomarker:** In **1995**, reduced cerebrospinal fluid (CSF) Aβ42 levels were shown to correlate with amyloid pathology, paving the way for modern biomarker‑driven diagnosis. > “The disease is a progressive loss of memory and other mental functions.” – **Alois Alzheimer** **INFOBOX:** - Full Name: Alzheimer disease (also Alzheimer’s disease) - Born: N/A - Died: N/A - Age: N/A - Nationality: N/A - Occupation: N/A - Active Years: 1906‑present (year first described) - Known For: Progressive neurodegeneration; amyloid‑β plaques & tau tangles - Awards: N/A - Spouse: N/A - Children: N/A - Height: N/A - Net Worth: N/A - World Records: N/A - Championships: N/A **FACTS:** - Birth Date: N/A (type: date) - Birth Place: N/A (type: location) - Death Date: N/A (type: date) - Career Start: 1906 (type: year) - Peak Achievement: Identification of amyloid‑β peptide (1984) (type: achievement) - Career Earnings: N/A (type: statistic) - World Record: N/A (type: record) - Famous Quote: “The disease is a progressive loss of memory and other mental functions.” (type: quote) - Fun Fact: Alzheimer disease accounts for **60‑80 % of all dementia** cases worldwide (type: trivia) - Legacy Stat: **≈ 6.2 million Americans** living with AD in 2023 (type: statistic) **TAGS:** alzheimer’s, dementia, neurodegeneration, neurology, genetics, epidemiology, treatment, history *This article is for educational purposes only. Always consult qualified health professionals for diagnosis, treatment, or medical advice.*
Health & MedicineAlzheimers Disease
Alzheimer's disease is a progressive, irreversible neurodegenerative disorder that affects memory, thinking, and behavior, ultimately leading to a decline in cognitive function and loss of bodily functions. ## Overview Alzheimer's disease (AD) is a complex and multifaceted condition that affects millions of people worldwide. It is the most common form of dementia, accounting for approximately 60-70% of cases. The disease is characterized by the progressive loss of memory, thinking, and behavioral abilities, ultimately leading to a decline in cognitive function and loss of bodily functions. Alzheimer's disease is a leading cause of disability and mortality among older adults, with the average life expectancy following diagnosis ranging from three to twelve years. The early symptoms of Alzheimer's disease often go unnoticed, but as the disease advances, individuals may experience problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues. As the condition declines, individuals may withdraw from family and society, leading to social isolation and decreased quality of life. Alzheimer's disease is a devastating condition that affects not only the individual but also their loved ones, caregivers, and the broader community. ## History/Background Alzheimer's disease was first described by Alois Alzheimer in 1906, a German psychiatrist and neuropathologist who identified the disease in a 51-year-old woman named Auguste Deter. Alzheimer's groundbreaking work led to the discovery of the disease's characteristic histopathological features, including amyloid plaques and neurofibrillary tangles. Since then, significant advances have been made in understanding the disease's underlying mechanisms, diagnosis, and treatment. In the early 20th century, Alzheimer's disease was considered a rare condition, but as the population aged, the prevalence of the disease increased. In the 1970s and 1980s, researchers began to develop diagnostic criteria for Alzheimer's disease, which led to a better understanding of the disease's progression and impact on individuals and families. Today, Alzheimer's disease is recognized as a major public health concern, with an estimated 50 million people worldwide living with the disease. ## Key Information ### **Causes and Risk Factors** While the exact causes of Alzheimer's disease are still unknown, research suggests that a combination of genetic, environmental, and lifestyle factors contribute to the development of the disease. Risk factors include: * Age: Alzheimer's disease is a degenerative condition that affects older adults, with the majority of cases occurring after the age of 65. * Family history: Individuals with a family history of Alzheimer's disease are more likely to develop the disease. * Genetics: Certain genetic mutations, such as APOE-e4, increase the risk of developing Alzheimer's disease. * Lifestyle factors: Physical inactivity, social isolation, and poor diet may contribute to the development of Alzheimer's disease. ### **Symptoms and Stages** The symptoms of Alzheimer's disease can be divided into three stages: 1. **Early-stage Alzheimer's**: Individuals may experience mild cognitive impairment, including difficulty with memory, language, and problem-solving. 2. **Moderate-stage Alzheimer's**: Symptoms worsen, and individuals may experience significant cognitive decline, including difficulty with daily activities and communication. 3. **Late-stage Alzheimer's**: Individuals may experience severe cognitive decline, including loss of motor function, incontinence, and difficulty with swallowing. ### **Diagnosis and Treatment** Diagnosing Alzheimer's disease can be challenging, as the symptoms can be similar to other conditions. A comprehensive diagnostic evaluation, including medical history, physical examination, laboratory tests, and cognitive assessments, is necessary to confirm the diagnosis. While there is currently no cure for Alzheimer's disease, various treatments can help manage symptoms and slow disease progression, including: * **Cholinesterase inhibitors**: Medications that increase the levels of acetylcholine in the brain, which can help improve cognitive function. * **Memantine**: A medication that blocks the action of glutamate, a neurotransmitter that can contribute to the development of Alzheimer's disease. * **Non-pharmacological interventions**: Behavioral therapies, such as cognitive training and support groups, can help individuals and families cope with the disease. ## Significance Alzheimer's disease has a significant impact on individuals, families, and society as a whole. The disease affects not only the individual but also their loved ones, caregivers, and the broader community. Alzheimer's disease is a leading cause of disability and mortality among older adults, with significant economic and social costs. Understanding the disease's underlying mechanisms, diagnosis, and treatment is essential to developing effective interventions and improving the quality of life for individuals and families affected by the disease. INFOBOX: - Name: Alzheimer's disease - Type: Neurodegenerative disorder - Date: 1906 (first described by Alois Alzheimer) - Location: Global - Known For: Most common form of dementia, leading cause of disability and mortality among older adults TAGS: Neurodegenerative disease, dementia, Alzheimer's disease, cognitive impairment, memory loss, aging, public health, healthcare, gerontology.